Microsoft Word - 1. Announcement - LITIGATION AGAINST A NINGBO SUBSIDIARY

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of

Hong Kong Limited

take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this a nnouncement.

LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability )

(Stock code: 503) INSIDE INFORMATION LITIGATION AGAINST A NINGBO SUBSIDIARY

Lansen
Pharmaceutical Holdings Limited (the "Company", together with
its subsidiaries, the
"Group") makes this announcement pursuant to Rule 13.09 of the Rules Governing the Listing of
Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions
(as defined in the
Listing Rules) under
Part XIVA
of the Securities and Futures Ordinance
(Chapter 571, Laws of Hong Kong).
The board (the "Board") of directors (the "Director(s)") of the Company w ishes to inform the
shareholders of the Company and potential investors that it has recently come to the attention of
the Company that
深圳海 王 藥業有限 公 司 (Neptunus Medicine Comp any Limited*) (the
"Claimant"), a subsidiary of 深圳海王生物工程股份有限公司 (Shenzhen Neptunus Biological
Engineering Company Limited*) ("Shenzhen Neptunus") has
initiated legal proceedings as
plaintiff (the "Litigation") against Ningbo Liwah Pharmaceutical Compan y Limited ("Ningbo Liwah"), a wholly owned subsidiary of the Company in Ningbo, the People' s Republic of China ("PRC"). According to an announcement published by Shenzhen Neptunus, the Claimant had
submitted a writ of summons at Shenzhen Intermediate People's Court (深圳市中級人民法院),
and the court had issued a notice of case acceptance (受理案件通知書). A s at the date of this announcement, Ningbo Liwah has not received any court documents in relatiion to the Litigation.
In the Litigation, the Claimant alleged that it had suffered several losses due tto the use of ginkgo
extract
supplied by Ningbo
Liwah in the Claimant's products. The Claimant therefore seeks
damages of RMB70,037,595 as well as relevant legal fees.
The Company has sought a preliminary opinion on the Litigation from its legal counsel in the PRC, who, based on the information available as of the date of this announcement, is of the opinion that the amount claimed by the Claimant is highly disputable. The Company will, in accordance with the relevant laws, make every effort to protect its interests and its shareholders' interests, actively respond to the case and defend its position vigorously. The Company will closely monitor the development of this matter and make further announcement if and when there is any significant development in respect of this matter.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Lansen Pharmaceutical Holdings Limited Stephen Burnau Hunt

Chairman

Hong Kong, 6 July 2015

As at the date of this announcement, the executive Director is Mr. Liu Bang Min; the non- executive Directors are Mr. Stephen Burnau Hunt, Mr. Lee Jin Yi, Ms. Yip Pui Ling, Rebecca, Mr. Tang Jun and Ms. Tao Fang Fang; the independent non-executive Directors are Mr. Chan KeeHuen, Michael, Mr. Tang Chiu Ping, Raymond and Mr. Fritz Heinrich Horlacher.

* For identification purpose only

2

distributed by